-
1Academic Journal
Authors: M. V. Kchachaturov, N. A. Tsareva, S. N. Avdeev, М. В. Хачатуров, Н. А. Царева, С. Н. Авдеев
Contributors: The study was not sponsored, Спонсорская поддержка отсутствовала
Source: PULMONOLOGIYA; Том 34, № 6 (2024); 887-895 ; Пульмонология; Том 34, № 6 (2024); 887-895 ; 2541-9617 ; 0869-0189
Subject Terms: тромбоксан, bone morphogenetic protein, platelet growth factor, mitochondrial dysfunction, serotonin, estrogen, monoclonal antibodies, thromboxane, костный морфогенетический белок, тромбоцитарный фактор роста, митохондриальная дисфункция, серотонин, эстроген, моноклональные антитела
File Description: application/pdf
Relation: https://journal.pulmonology.ru/pulm/article/view/4326/3724; https://journal.pulmonology.ru/pulm/article/downloadSuppFile/4326/2072; https://journal.pulmonology.ru/pulm/article/downloadSuppFile/4326/2073; https://journal.pulmonology.ru/pulm/article/downloadSuppFile/4326/2074; https://journal.pulmonology.ru/pulm/article/downloadSuppFile/4326/2075; Humbert M., Kovacs G., Hoeper M.M. et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: Developed by the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Endorsed by the International Society for Heart and Lung Transplantation (ISHLT) and the European Reference Network on rare respiratory diseases (ERN-LUNG). Eur. Heart J. 2022; 43 (38): 3618–3731. DOI:10.1093/eurheartj/ehac237.; Xiao Y., Chen P.P., Zhou R.L. et al. Pathological mechanisms and potential therapeutic targets of pulmonary arterial hypertension: a review. Aging. Dis. 2020; 11 (6): 1623–1639. DOI:10.14336/AD.2020.0111.; Qaiser K.N., Tonelli A.R. Novel treatment pathways in pulmonary arterial hypertension. Methodist Debakey Cardiovasc. J. 2021; 17 (2): 106–114. DOI:10.14797/CBHS2234.; Guignabert C., Humbert M. Targeting transforming growth factor-β receptors in pulmonary hypertension. Eur. Respir. J. 2021; 57 (2): 2002341. DOI:10.1183/13993003.02341-2020.; Sherman M.L., Borgstein N.G., Mook L. et al. Multiple-dose, safety, pharmacokinetic, and pharmacodynamic study of sotatercept (ActRIIA-IgG1), a novel erythropoietic agent, in healthy postmenopausal women. J. Clin. Pharmacol. 2013; 53 (11): 1121–1130. DOI:10.1002/jcph.160.; Yung L.M., Yang P., Joshi S. et al. ACTRIIA-Fc rebalances activin/GDF versus BMP signaling in pulmonary hypertension. Sci. Transl. Med. 2020; 12 (543): eaaz5660. DOI:10.1126/scitranslmed.aaz5660.; Hoeper M.M., Badesch D.B., Ghofrani H.A. et al. Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension. N. Engl. J. Med. 2023; 388 (16): 1478–1490. DOI:10.1056/NEJMoa2213558.; Araya A.A., Tasnif Y. Tacrolimus. Treasure Island (FL): StatPearls Publishing; 2023. Available at: https://www.ncbi.nlm.nih.gov/books/NBK544318/; Spiekerkoetter E., Tian X., Cai J. et al. FK506 activates BMPR2, rescues endothelial dysfunction, and reverses pulmonary hypertension. J. Clin. Invest. 2013; 123 (8): 3600–3613. DOI:10.1172/JCI65592.; Spiekerkoetter E., Sung Y.K., Sudheendra D. et al. Randomised placebo-controlled safety and tolerability trial of FK506 (tacrolimus) for pulmonary arterial hypertension. Eur. Respir. J. 2017; 50 (3): 1602449. DOI:10.1183/13993003.02449-2016.; Perros F., Montani D., Dorfmüller P. et al. Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 2008; 178 (1): 81–88. DOI:10.1164/rccm.200707-1037OC.; Medarametla V., Festin S., Sugarragchaa C. et al. PK10453, a nonselective platelet-derived growth factor receptor inhibitor, prevents the progression of pulmonary arterial hypertension. Pulm. Circ. 2014; 4 (1): 82–102. DOI:10.1086/674881.; Schermuly R.T., Dony E., Ghofrani H.A. et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J. Clin. Invest. 2005; 115 (10): 2811–2821. DOI:10.1172/JCI24838.; Hoeper M.M., Barst R.J., Bourge R.C. et al. Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation. 2013; 127 (10): 1128–1138. DOI:10.1161/CIRCULATIONAHA.112.000765.; Shah A.M., Campbell P., Rocha G.Q. et al. Effect of imatinib as add-on therapy on echocardiographic measures of right ventricular function in patients with significant pulmonary arterial hypertension. Eur. Heart J. 2015; 36 (10): 623–632. DOI:10.1093/eurheartj/ehu035.; Frantz R.P., Benza R.L., Channick R.N. et al. TORREY, a Phase 2 study to evaluate the efficacy and safety of inhaled seralutinib for the treatment of pulmonary arterial hypertension. Pulm. Circ. 2021; 11 (4): 20458940211057071. DOI:10.1177/20458940211057071.; Gossamer Bio. Gossamer Bio announces seralutinib meets primary endpoint in phase 2 torrey study in pah. Available at: https://ir.gossamerbio.com/news-releases/news-release-details/gossamer-bio-announces-seralutinib-meets-primary-endpoint-phase/; Archer S.L. Acquired mitochondrial abnormalities, including epigenetic inhibition of superoxide dismutase 2, in pulmonary hypertension and cancer: therapeutic implications. Adv. Exp. Med. Biol. 2016; 903: 29–53. DOI:10.1007/978-1-4899-7678-9_3.; Stephen Y. Chan, Lewis J. Rubin. Metabolic dysfunction in pulmonary hypertension: from basic science to clinical practice. Eur. Respir. Rev. 2017, 26 (146): 170094. DOI:10.1183/16000617.0094-2017.; Michelakis E.D., McMurtry M.S., Wu X.C. et al. Dichloroacetate, a metabolic modulator, prevents and reverses chronic hypoxic pulmonary hypertension in rats: role of increased expression and activity of voltage-gated potassium channels. Circulation. 2002; 105 (2): 244–250. DOI:10.1161/hc0202.101974.; Michelakis E.D., Gurtu V., Webster L. et al. Inhibition of pyruvate dehydrogenase kinase improves pulmonary arterial hypertension in genetically susceptible patients. Sci. Transl. Med. 2017; 9 (413): eaao4583. DOI:10.1126/scitranslmed.aao4583.; Rouhana S., Virsolvy A., Fares N. et al. Ranolazine: an old drug with emerging potential; Lessons from pre-clinical and clinical investigations for possible repositioning. Pharmaceuticals (Basel). 2021; 15 (1): 31. DOI:10.3390/ph15010031.; Han Y., Forfia P., Vaidya A. et al. Ranolazine improves right ventricular function in patients with precapillary pulmonary hypertension: results from a double-blind, randomized, placebo-controlled trial. J. Card. Fail. 2021; 27 (2): 253–257. DOI:10.1016/j.cardfail.2020.10.006.; Zolty R. Novel experimental therapies for treatment of pulmonary arterial hypertension. J. Exp. Pharmacol. 2021; 13: 817–857. DOI:10.2147/JEP.S236743.; Fukumoto Y., Yamada N., Matsubara H. et al. Double-blind, placebo-controlled clinical trial with a rho-kinase inhibitor in pulmonary arterial hypertension. Circ. J. 2013; 77 (10): 2619–2625. DOI:10.1253/circj.cj-13-0443.; ClinicalTrials.gov. Phase 2 study to assess safety, tolerability and efficacy of once weekly SC pemziviptadil (PB1046) in subjects with symptomatic PAH (VIP). 2022; No.NCT03556020. Available at: https://clinicaltrials.gov/study/NCT03556020; Liu Y., Fanburg B.L. Serotonin-induced growth of pulmonary artery smooth muscle requires activation of phosphatidylinositol 3-kinase/serine-threonine protein kinase B/mammalian target of rapamycin/p70 ribosomal S6 kinase 1. Am. J. Respir. Cell Mol. Biol. 2006; 34 (2): 182–191. DOI:10.1165/rcmb.2005-0163OC.; Hervé P., Launay J.M., Scrobohaci M.L. et al. Increased plasma serotonin in primary pulmonary hypertension. Am. J. Med. 1995; 99 (3): 249–254. DOI:10.1016/s0002-9343(99)80156-9.; Lazarus H.M., Denning J., Wring S. et al. A trial design to maximize knowledge of the effects of rodatristat ethyl in the treatment of pulmonary arterial hypertension (ELEVATE 2). Pulm. Circ. 2022; 12 (2): e12088. DOI:10.1002/pul2.12088.; Cassady S.J., Soldin D., Ramani G.V. Novel and emerging therapies in pulmonary arterial hypertension. Front. Drug Dis. 2022; 2. DOI:10.3389/fddsv.2022.1022971.; Kawut S.M., Archer-Chicko C.L., DeMichele A. et al. Anastrozole in pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. Am. J. Respir. Crit. Care Med. 2017; 195 (3): 360–368. DOI:10.1164/rccm.201605-1024OC.; Sitbon O., Gomberg-Maitland M., Granton J. et al. Clinical trial design and new therapies for pulmonary arterial hypertension. Eur. Respir. J. 2019; 53 (1): 1801908. DOI:10.1183/13993003.01908-2018.; ClinicalTrials.gov. Austin E. Tamoxifen Therapy to Treat Pulmonary Arterial Hypertension (T3PAH). 2022; No.NCT03528902. Available at: https://clinicaltrials.gov/study/NCT03528902; Haryono A.; Ramadhiani R.; Ryanto G.R.T. Emoto N. Endothelin and the cardiovascular system: the long journey and where we are going. Biology (Basel). 2022; 11 (5): 759. DOI:10.3390/biology11050759.; Zhang C., Jing S. Therapeutic antibody approach for pulmonary arterial hypertension. Int. J. Cardiol. Cardiovasc. Dis. 2021; 1 (1): 15–19. DOI:10.46439/cardiology.1.002.; Christman B.W., McPherson C.D., Newman J.H. et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N. Engl. J. Med. 1992; 327 (2): 70–75. DOI:10.1056/NEJM199207093270202.; Katugampola S.D., Davenport A.P. Thromboxane receptor density is increased in human cardiovascular disease with evidence for inhibition at therapeutic concentrations by the AT(1) receptor antagonist losartan. Br. J. Pharmacol. 2001; 134 (7): 1385–1392. DOI:10.1038/sj.bjp.0704416.; Mulvaney E.P., Reid H.M., Bialesova L. et al. NTP42, a novel antagonist of the thromboxane receptor, attenuates experimentally induced pulmonary arterial hypertension. BMC Pulm. Med. 2020; 20 (1): 85. DOI:10.1186/s12890-020-1113-2.; Savai R., Pullamsetti S.S., Kolbe J. et al. Immune and inflammatory cell involvement in the pathology of idiopathic pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 2012; 186 (9): 897–908. DOI:10.1164/rccm.201202-0335OC.; Liang S., Desai A.A., Black S.M., Tang H. Cytokines, chemokines, and inflammation in pulmonary arterial hypertension. Adv. Exp. Med. Biol. 2021; 1303: 275–303. DOI:10.1007/978-3-030-63046-1_15.; Prins K.W., Archer S.L., Pritzker M. et al. Interleukin-6 is independently associated with right ventricular function in pulmonary arterial hypertension. J. Heart Lung Transplant. 2018; 37 (3): 376–384. DOI:10.1016/j.healun.2017.08.011.; Toshner M., Rothman A. IL-6 in pulmonary hypertension: why novel is not always best. Eur. Respir. J. 2020; 55 (4): 2000314. DOI:10.1183/13993003.00314-2020.; Trankle C.R., Canada J.M., Kadariya D. et al. IL-1 blockade reduces inflammation in pulmonary arterial hypertension and right ventricular failure: a single-arm, open-label, phase IB/II pilot study. Am. J. Respir. Crit. Care Med. 2019; 199 (3): 381–384. DOI:10.1164/rccm.201809-1631LE.; Bell R.D., White R.J., Garcia-Hernandez M.L. et al. Tumor necrosis factor induces obliterative pulmonary vascular disease in a novel model of connective tissue disease-associated pulmonary arterial hypertension. Arthritis Rheumatol. 2020; 72 (10): 1759–1770. DOI:10.1002/art.41309.; O'Brien J., Hayder H., Zayed Y., Peng C. Overview of microRNA biogenesis, mechanisms of actions, and circulation. Front. Endocrinol. (Lausanne). 2018; 9: 402. DOI:10.3389/fendo.2018.00402.; Sindi H.A., Russomanno G., Satta S. et al. Therapeutic potential of KLF2-induced exosomal microRNAs in pulmonary hypertension. Nat. Commun. 2020; 11 (1): 1185. DOI:10.1038/s41467-020-14966-x.; Dhoble S., Patravale V., Weaver E. et al. Comprehensive review on novel targets and emerging therapeutic modalities for pulmonary arterial Hypertension. Int. J. Pharm. 2022; 621: 121792. DOI:10.1016/j.ijpharm.2022.121792.; https://journal.pulmonology.ru/pulm/article/view/4326
-
2
-
3
-
4Academic Journal
Authors: U. F. Mukhametov, S. V. Lyulin, D. Yu. Borzunov
Source: Креативная хирургия и онкология, Vol 12, Iss 4, Pp 337-344 (2023)
Subject Terms: хирургия позвоночника, реконструктивная хирургия, костнозаменяющие материалы, гидроксиапатит, антибиотики, костный морфогенетический белок, биосовместимые материалы, кальция фосфаты, Surgery, RD1-811, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Relation: https://www.surgonco.ru/jour/article/view/741; https://doaj.org/toc/2307-0501; https://doaj.org/toc/2076-3093; https://doaj.org/article/d953c7155f384f43b6ed0310eaf9c34c
-
5Academic Journal
Authors: L. A. Bardonova, E. G. Belykh, V. A. Byvaltsev, Л. А. Бардонова, Е. Г. Белых, В. А. Бывальцев
Source: Acta Biomedica Scientifica; Том 1, № 4 (2016); 99-103 ; 2587-9596 ; 2541-9420
Subject Terms: протеогликаны, degeneration, bone morphogenetic protein, proteoglycans, дегенерация, костный морфогенетический белок
File Description: application/pdf
Relation: https://www.actabiomedica.ru/jour/article/view/250/251; Булатов А.А., Савельев В.И., Калинин А.В. Применение костных морфогенетических белков в эксперименте и клинике // Травматология и ортопедия России. - 2005. - № 1 (34). - С. 46-54; Бывальцев В.А., Степанов И.А., Белых Е.Г., Гиерс М., Прул М. Цитокиновые механизмы дегенерации межпозвонкового диска // Сибирский медицинский журнал. - 2015. - № 5. - С. 17-21; Belykh E, Giers M, Bardonova L, Theodore N, Preul M, Byvaltsev V (2015). The role of bone morphogenetic proteins 2, 7, and 14 in approaches for intervertebral disk restoration. World Neurosurg., 84 (4), 870-877.; Coulson-Thomas V, Gesteira TF (2014). Dimeth-ylmethylene Blue Assay (DMMB). Bio-protocol, 4 (18), e1236. Available at: http://www.bio-protocol.org/e1236.; Farndale RW, Buttle DJ, Barrett AJ (1986). Improved quantitation and discrimination of sulphated glycosaminoglycans by use of dimethylmethylene blue. Biochim. Biophys. Acta., (883), 173-177.; Gantenbein B, Illien-Jünger S, Chan SC, Walser J, Haglund L, Ferguson SJ, Iatridis JC, Grad S (2015). Organ culture bioreactors - platforms to study human intervertebral disc degeneration and regenerative therapy. Curr. Stem. Cell Res. Ther, 10 (4), 339-352.; Haschtmann D, Ferguson SJ, Stoyanov JV (2012). BMP-2 and TGF-ß3 do not prevent spontaneous degeneration in rabbit disc explants but induce ossification of the annulus fibrosus. Eur. Spine J., 21 (9), 1724-1733.; Huang YC, Urban JP, Luk KD (2014). Intervertebral disc regeneration: do nutrients lead the way? Nat. Rev. Rheumatol., 10 (9), 561-566.; Kraemer J (2009). Intervertebral disk diseases: causes, diagnosis, treatment, prophylaxis, 368.; Le Maitre CL, Richardson SM, Baird P, Freemont AJ, Hoyland JA (2005). Expression of receptors for putative anabolic growth factors in human intervertebral disc: implications for repair and regeneration of the disc. J. Pathol, 207 (4), 445-452.; Lo KW, Ulery BD, Ashe KM, Laurencin CT (2012). Studies of bone morphogenetic protein-based surgical repair. Adv. Drug. Deliv. Rev., 64 (12), 1277-1291.; Louis KS, Siegel AC (2011). Cell viability analysis using trypan blue: manual and automated methods. Methods Mol. Biol., (740), 7-12.; Nolan JS, Packer L (1974). Monolayer culture techniques for normal human diploid fibroblasts. Meth. Enzymol., 32 (B), 561-568.; Raj PP (2008). Intervertebral disc: anatomyphysiology-pathophysiology-treatment, Pain Pract., (8), 18-44.; Tomaszewski KA, Walocha JA, Mizia E, Gla-dysz T, Glowacki R, Tomaszewska R (2015). Age- and degeneration-related variations in cell density and glycosaminoglycan content in the human cervical intervertebral disc and its endplates. Pol. J. Pathol., 66 (3), 296-309.; Urban JP, Smith S, Fairbank JC (2004). Nutrition of the intervertebral disc, Spine (Phila Pa 1976), (29), 2700-2709.; https://www.actabiomedica.ru/jour/article/view/250
-
6Academic Journal
-
7Academic Journal
Authors: Попков, Арнольд
Subject Terms: ИМПЛАНТ, БИОКЕРАМИКА, ОСТЕОИНДУКЦИЯ, ОСТЕОКОНДУКЦИЯ, БИОПОЛИМЕРЫ, НАНОПОКРЫТИЯ, КОСТНЫЙ МОРФОГЕНЕТИЧЕСКИЙ БЕЛОК, БИОАКТИВНОСТЬ
File Description: text/html
-
8Academic Journal
Authors: Семенов, Павел
Subject Terms: ИМПЛАНТАТ, КОСТНАЯ ТКАНЬ, РЕМОДЕЛИРОВАНИЕ, КОСТНЫЙ МОРФОГЕНЕТИЧЕСКИЙ БЕЛОК 2
File Description: text/html
-
9Academic Journal
Source: Журнал фундаментальной медицины и биологии.
File Description: text/html
-
10Academic Journal
Source: Гены и клетки.
Subject Terms: ПЛАЗМИДЫ,КОСТНЫЙ МОРФОГЕНЕТИЧЕСКИЙ БЕЛОК 2,BMP2,СОСУДИСТЫЙ ЭНДОТЕЛИАЛЬНЫЙ ФАКТОР РОСТА,VEGF,МЕЗЕНХИМНЫЕ СТРОМАЛЬНЫЕ КЛЕТКИ,ОСТЕОГЕННАЯ ДИФФЕРЕНЦИРОВКА,ХОНДРОГЕННАЯ ДИФФЕРЕНЦИРОВКА,АНГИОГЕНЕЗ,PLASMIDS,BONE MORPHOGENETIC PROTEIN 2,VASCULAR ENDOTHELIAL GROWTH FACTOR,MESENCHYMAL STEM CELLS,OSTEOGENESIS DIFFERENTIATION,CHONDROGENIC DIFFERENTIATION,ANGIOGENESIS, 3. Good health
File Description: text/html
-
11Academic Journal
Source: Гений ортопедии.
Subject Terms: 03 medical and health sciences, 0302 clinical medicine, ИМПЛАНТ, БИОКЕРАМИКА, ОСТЕОИНДУКЦИЯ, ОСТЕОКОНДУКЦИЯ, БИОПОЛИМЕРЫ, НАНОПОКРЫТИЯ, КОСТНЫЙ МОРФОГЕНЕТИЧЕСКИЙ БЕЛОК, БИОАКТИВНОСТЬ
File Description: text/html
-
12Academic Journal
Source: Вестник Волгоградского государственного университета. Серия 9: Исследования молодых ученых.
File Description: text/html
-
13Academic Journal
Authors: Sagalovsky, Stanislav, Schоnert, Matthias
Source: ORTHOPAEDICS, TRAUMATOLOGY and PROSTHETICS; № 3 (2014); 136-143
Ортопедия, травматология и протезирование; № 3 (2014); 136-143Subject Terms: 03 medical and health sciences, 0302 clinical medicine, остеогенез, загоєння перелому кістки, трансформувальний фактор росту-β1, кістковий морфогенетичний білок, osteogenesis, bone fracture healing, transforming growth factor β-1, bone morphogenic protein, заживление перелома кости, трансформирующий фактор роста бета-1, костный морфогенетический белок
File Description: application/pdf
